If you are wondering whether GSK shares still offer value at around £18.86, you are not alone. The stock has been attracting ...

GSK is shifting to specialty growth (HIV, oncology, asthma) with key launches and a deep late-stage pipeline—still ...

GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK plc has disclosed that David Redfern, President of Corporate Development, and Victoria ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

GSK plc (NYSE:GSK) is one of the best performing pharma stocks in 2025. Jefferies reaffirmed a Buy rating on GSK plc ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a positive ...

GSK plc (NYSE:GSK) and Spero Therapeutics Inc (NASDAQ:SPRO) on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) ...

GSK and Ionis report strong Phase 3 results for a hepatitis B drug that improved cure rates and could support regulatory filings in early 2026.